



UNIVERSITI PUTRA MALAYSIA

***ANTI-ANGIOGENIC POTENTIAL OF ARDISIA CRISPA ROOTS ETHANOLIC
EXTRACT AND ITS QUINONE-RICH FRACTION IN MICE***

DAYANG ERNA ZULAIKHA AWANG HAMSIN

FPSK(m) 2013 33



ANTI-ANGIOGENIC POTENTIAL OF *Ardisia crispera* ROOTS ETHANOLIC EXTRACT AND ITS QUINONE-RICH FRACTION IN MICE

**DAYANG ERNA ZULAIKHA BT AWANG
HAMSIN**

**MASTER OF SCIENCE
UNIVERSITI PUTRA MALAYSIA**

2013



**ANTI-ANGIOGENIC POTENTIAL OF *Ardisia crispa* ROOTS ETHANOLIC
EXTRACT AND ITS QUINONE-RICH FRACTION IN MICE**

By

DAYANG ERNA ZULAIKHA BT AWANG HAMSIN

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia,
in Fulfilment of the Requirements for the Degree of Master of Science**

July 2013

COPYRIGHT

All material contained within the thesis, including without limitation text, logos, icons, photographs and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfillment
of the requirement for the Degree of Master of Science

**ANTI-ANGIOGENIC POTENTIAL OF *Ardisia crispa* ROOTS ETHANOLIC
EXTRACT AND ITS QUINONE-RICH FRACTION IN MICE**

By

DAYANG ERNA ZULAIKHA BT AWANG HAMSIN

July 2013

Chair: Roslida Abd Hamid @ Abd Razak, PhD

Faculty: Medicine and Health Sciences

Angiogenesis is the process of blood vessel formation which plays a crucial role in normal physiology, and also in the progression of various chronic diseases such as cancer, arthritis and such. As targeting angiogenesis has become an important strategy in the search of treatments of various debilitating ailments, it is a need-based study to identify a natural source of anti-angiogenic agent that may halt the progression of angiogenesis event. *Ardisia crispa*, locally known as “mata itik” (Family: Myrsinaceae) has been used in traditional Malay medicine to treat various ailments related to inflammation. *Ardisia crispa* roots have been shown to treat various inflammation-related diseases in several previous studies. As angiogenesis is strongly correlated with inflammation, the aim of the present study was to evaluate anti-angiogenic potential of the hexane partition of *Ardisia crispa* roots ethanolic extract (ACRH) and its quinone- rich fraction (QRF) on several experimental models, namely Miles vascular permeability test, murine air pouch granuloma and mouse sponge implantation test. Preliminary cyclooxygenase and soy lipoxygenase inhibitory study were also conducted to elucidate the possible pathways involved.

Preliminary phytochemical screening of ACRH indicated the abundant presence of flavonoid, triterpene and tannin. Quinone- rich fraction (QRF) was separated from ACRH (38.33% w/w) and further isolated to yield a compound, namely fAC-2, indicated by a single TLC spot at R_f : 0.76. The compound was later found to be impure, when later analysed with GC-MS. Nevertheless, fAC-2 was elucidated to possess a major constituent of a benzoquinonoid compound (2-methoxy-6-undecyl-1, 4-benzoquinone), when compared with the standard data. Both ACRH and QRF were also quantified using high performance liquid chromatography (HPLC). For toxicity study, the LD_{50} value of ACRH was found to be 617.02 mg/kg. In Miles vascular permeability assay, the lowest dose of both ACRH and QRF (10 mg/kg) produced significant reduction in VEGF-induced hyperpermeability compared to vehicle control. In murine air pouch granuloma, ACRH and QRF displayed significant and dose-dependent angiogenic and inflammatory inhibition, in which significant reduction of vascular index and granuloma tissue weight was observed at high dose (100 mg/kg). ACRH and QRF were also shown to possess selective COX-2 inhibitory properties which were dose-dependent, though COX-1 inhibition was also observed in a lower percentage. On the other hand, ACRH and QRF did not exhibit LOX inhibitory activity. Interestingly, fAC-2 showed its selectivity towards the inhibition of COX-2, instead of COX-1, and showed to be a moderate LOX inhibitor. Thus, it can be concluded that *Ardisia crispera* roots showed potential anti-angiogenic properties by partly mediating COX-2 activity, as shown in the *in vitro* screening, and it is postulated that fAC-2 (2-methoxy-6-undecyl-1, 4-benzoquinone) displays dual COX-2 and LOX once it is purely isolated in a large scale and tested *in vivo*.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Master Sains

POTENSI AKAR *Ardisia crisper* EKSTRAK ETANOL DAN FRAKSI KAYA KUINON SEBAGAI PERENCAT PEMBENTUKAN SALUR DARAH KE ATAS MENCIT

Oleh

DAYANG ERNA ZULAIKHA BT AWANG HAMSIN

Julai 2013

Pengerusi: Roslida Abd Hamid @ Abd Razak, PhD

Fakulti: Perubatan dan Sains Kesihatan

Pembentukan salur darah merupakan satu proses yang penting dalam fisiologi normal, dan juga penting dalam perkembangan pelbagai jenis penyakit kronik seperti kanser, radang otot, dan sebagainya. Oleh sebab pensasaran pembentukan salur darah semakin menjadi strategi yang penting dalam pencarian rawatan bagi pelbagai penyakit, adalah penting untuk kajian dijalankan bagi mengenal pasti sumber semulajadi bagi agen perencat pembentukan salur darah, yang mampu merencat perkembangan proses yang berlaku di dalam penghasilan salur darah. *Ardisia crisper* (Famili: Myrsinaceae) yang juga dikenali sebagai pokok mata itik, telah lama digunakan dalam perubatan tradisional Melayu untuk mengubati penyakit yang berkaitan dengan keradangan. Akar *Ardisia crisper* telah terbukti mampu merawat pelbagai penyakit yang berkaitan dengan keradangan melalui beberapa kajian yang dijalankan sebelum ini. Oleh sebab terdapat korelasi yang kuat antara keradangan dan pembentukan salur darah, objektif penyelidikan ini dilakukan adalah untuk mengetahui sama ada partisi heksana (ACRH) daripada ekstrak mentah akar pokok *Ardisia crisper*, beserta fraksi kaya kuinon (QRF) mempunyai aktiviti merencat

pembentukan salur darah dalam beberapa model eksperimen, termasuk ujian ketelapan vaskular Miles, granuloma kantung udara murin dan ujian implan span dalam mencit. Kajian awal terhadap penglibatan enzim siklooksigenase (COX) dan lipoksigenase (LOX) juga dijalankan untuk mengenalpasti mekanisma yang mungkin terlibat dalam perencatan formasi salur darah. Kajian awal terhadap komposisi fitokimia ACRH menunjukkan bahawa ACRH mengandungi sebatian-sebatian flavonoid, triterpena dan tannin yang banyak. Fraksi kaya kuinon (QRF) telah dipisahkan daripada ACRH (38.33% w/w) dan seterusnya diasingkan untuk menghasilkan satu sebatian utama (fAC-2) berdasarkan bintik tunggal pada plat Kromatografi Lapisan Nipis (KLN) pada R_f :0.76. Sebatian tersebut kemudiannya didapati tidak tulen melalui analisis Kromatografi Gas-Spektroskopi Jisim (KG-SJ). Walaubagaimanapun sebatian benzokuinon iaitu 2-metoksi-6-undesil-1,4-benzokuinon dibuktikan merupakan komponen utama dalam sebatian tersebut, (fAC-2) apabila dibandingkan dengan data piawai. ACRH dan QRF juga diukur dengan menggunakan kromatografi cecair prestasi tinggi (KCPT). Untuk kajian ketoksikan, nilai LD_{50} bagi ACRH telah dikenalpasti sebagai 617.02 mg/kg. Dalam ujian ketelapan vaskular Miles, dos terendah bagi ACRH and QRF (10 mg/kg) menghasilkan pengurangan yang signifikan dalam ketelapan hiper yang dirangsang oleh VEGF. Dalam granuloma kantung udara murin, ACRH and QRF menunjukkan kebergantungan dos yang signifikan dalam perencatan formasi salur darah dan keradangan, di mana pengurangan yang signifikan dalam indeks vaskular, dan juga berat kasar tisu granuloma juga dapat diamati. Aktiviti perencatan formasi saluran darah oleh ACRH and QRF telah terbukti disebabkan oleh enzim siklooksigenase-2 (COX-2) secara selektif, walaupun aktiviti enzim siklooksigenase-1 (COX-1) juga direncat, dalam peratusan yang lebih rendah. Walaubagaimanapun, sebatian fAC-2

telah terbukti menunjukkan sifatnya yang selektif terhadap perencatan aktiviti COX-2, berbanding COX-1. Sebatian fAC-2 juga menunjukkan perencatan yang baik terhadap enzim LOX soya. Kesimpulannya, akar *Ardisia crispa* menunjukkan potensi sebagai perencat formasi salur darah, dengan sebahagiannya melalui perencatan aktiviti enzim COX secara selektif, terbukti melalui ujian penyaringan *in vitro*. Walaubagaimanapun, sebatian fAC-2 berpotensi untuk menjadi agen perencat dwienzim COX-2 dan LOX setelah diasingkan dan dituliskan melalui skala besar dan diuji secara *in vivo* pada masa yang akan datang.

ACKNOWLEDGEMENTS

Bismillahirrahmanirrahim.

I would like to sincerely thank my supervisor, Dr Roslida Abd Hamid and co-supervisors, Dr Latifah Saiful Yazan and Dr Che Norma Mat Taib for the kind assistance and guidance throughout my journey of completing this Master's degree. I am also grateful to be having such a helpful group of peoples in Pharmacology Laboratory; many thanks to Joyce Yeong, Hamizah Sulaiman, Wan Nurul Husna Nordin, fellow labmates, and laboratory staffs for their kind support and generous help.

I would like to dedicate my special thanks to my family and husband, Awang Arshad Awang Kamis for giving me endless support from the start until the completion of my Master's degree. Without the kind encouragement and prayers from them, I would not be able to carry on and complete my Master's degree successfully. I appreciate the loving and kind support given very much.

Last but not least, I would also like to express my gratitude to Ministry of Higher Education and UNIMAS for giving me the SLAB scholarship to further my study. Without the opportunity given, I will not be able to taste the intense satisfaction of completing a research and I will never experience the challenges that have made me grow so much to become a better person I am today.

"A path without a heart is never enjoyable. On the other hand, a path with heart is easy— it does not make a warrior work at liking it; it makes for a joyful journey; as long as a man follows it, he is one with it."

Carlos Castaneda



LIST OF TABLES

Table		Page
2.1	Events of angiogenesis.	10
2.2	Angiogenic activators and its functions.	14
2.3	Angiogenic inhibitors and its functions.	17
2.4	<i>Ardisia</i> species and its medicinal properties.	48
3.1	Colour indications and the interpretation for different qualitative phytochemical tests.	67
3.2	Experimental design for Miles vascular permeability test.	75
3.3	Experimental design for mouse implantation method.	79
3.4	Experimental design for murine air pouch granuloma.	82
3.5	Protocols involved in each wells.	86
4.1	Extracts and properties of ACRE and ACRH.	90
4.2	Qualitative phytochemical analysis of ACRH	90
4.3	Chemical characteristics of compound resembling AC-2 (standard compound) in rich fraction	95
4.4	Mass breakdown of a major compounds consisted in AC-2.	97
4.5	Quantification of modified Miles assay performed in mice after induction of vessel permeability using VEGF in ACRH and QRF; extracted dye contents were quantified by measuring at 620 nm.	107
4.6	Effects of hexane fraction of <i>Ardisia crispa</i> roots (ACRH) and its quinone-rich fraction (QRF) on vascular index (VI) in murine air pouch granuloma	110
4.7	Effects of hexane fraction of <i>Ardisia crispa</i> roots (ACRH) and its quinone-rich fraction (QRF) on granuloma tissue dry weight (g) in murine air pouch granuloma	112
4.8	Mean vascular density (MVD) following various treatments	114
4.9	IC ₅₀ of different treatments in cyclooxygenase inhibitory assay	119
4.10	Percentage of inhibitions of COX-1 and COX-2 following treatments.	120
4.11	IC ₅₀ of different treatments in soy LOX inhibitory assay.	126
4.12	The percentage of inhibition of soy lipoxygenase following different treatment	127

LIST OF FIGURES

Figure		Page
2.1	Sequential steps of angiogenesis.	9
2.2	Conversion of arachidonic acids into it different metabolites by COXs and LOXs and clinically used classes of inhibitors.	23
2.3	Products of arachidonic metabolism via COX-1 or COX-2 activity.	25
2.4	The examples of classical NSAIDs. (a) Aspirin; (b) Ibuprofen; and (c) Indomethacin.	36
2.5	The examples of COX-2 inhibitors. (a) Celecoxib; (b) Rofecoxib	39
2.6	Selective 5-lipoxygenase (5-LOX) inhibitor (Zileuton).	41
2.7	Chemical structure of licofelone (ML-3000).	43
2.8	Chemical structures of Flavocoxid; (a) baicalin; (b) catechin.	44
2.9	<i>Ardisia crispa</i> plant.	51
2.10	Illustration of <i>Ardisia crispa</i> (Synonym: <i>Ardisia crenata</i> Sims 2). (1) roots systems; (2) flowering branchlet; (3) fruiting branch.	52
2.11	Chemical structures of AC7-1 (2-methoxy-6-tridecyl-1,4-benzoquinone).	55
2.12	Chemical structures of; (a) Ardisiacrispin A; (b) Ardisiacrispin B.	56
2.13	Chemical structure of FR900359.	57
3.1	A summarised figure of the assays conducted to evaluate anti-angiogenesis activity of <i>Ardisia crispa</i> roots extract and rich fraction.	60
3.2	The flow chart of <i>Ardisia crispa</i> roots extraction, fractionation and isolation.	64
3.3	Depiction of TLC plate. (a), (b) and (c) were the initial spots while (i) and (ii) were spots developed	70
3.4	Flow chart of LD ₅₀ determination of ACRH crude extract.	74
3.5	Flow chart of vascular permeability test of ACRH and its rich fraction.	78
3.6	Treatments in murine air pouch granuloma.	84
4.1	TLC-guided chromatographic isolation (AC-2 R _f : 0.76).	92
4.2	Comparison of R _f of benzoquinonoid compound in AC-2 with similar compound in	94

	fraction 3 (QRF), and fAC-2(Benzoquinoid rich fraction). Spots were resolved using chloroform as developing solvent.	
4.3	fAC-2 obtained following refractionation of QRF, in dark yellow colour.	94
4.4	Gas chromatogram of AC-2 (reference) separated using gas chromatography technique. Peak 2 was found to be compatible with 2-methoxy-6-undecyl-1, 4-benzoquinone based on its similar molecular ion peak and consistent mass fragmentation.	98
4.5	Spectral mass breakdown of a major compound of AC-2 at min 39.536.	99
4.6	Spectral mass breakdown of a major compound in AC-2 at min 42.992.	100
4.7	High performance liquid chromatography (HPLC) fingerprint of ACRH.	102
4.8	High performance liquid chromatography (HPLC) fingerprint of QRF.	103
4.9	High performance liquid chromatography (HPLC) fingerprint for AC-2.	104
4.10	Graphical method for determination of LD ₅₀ .	105
4.11	Percentage of VEGF-induced vascular permeability suppression (%) following pre-treatment of ACRH and QRF at three different doses (10, 30, and 100 mg/kg), compared to positive control (indomethacin 10 mg/kg). The treatment groups were compared with indomethacin as vehicle control was used in the calculation of vascular permeability suppression (%). The formula was $[(OD_{\text{vehicle control}} - OD_{\text{treatment}})/OD_{\text{vehicle control}}] \times 100\%$.	108
4.12	Microphotograph of a section showing blood vessels around gel impregnated with VEGF alone. Red arrow indicated the blood vessels (x200).	115
4.13	Microphotograph of a section showing blood vessels around gel impregnated with VEGF and DMSO (vehicle). Red arrows indicated the blood vessels (x200).	115
4.14	Microphotograph of a section showing occasional blood vessels around gel impregnated with VEGF and licofelone. Red arrows indicated the blood vessels (x200).	116
4.15	Microphotograph of a section showing occasional blood vessels around gel impregnated with VEGF and ACRH. Red arrows indicted the blood vessels (x200).	116

4.16	Microphotograph of a section showing occasional blood vessels around gel impregnated with VEGF and QRF. Red arrows indicated the blood vessels (x200).	117
4.17	COX-1 and COX-2 inhibition of Aspirin in various concentrations.	121
4.18	COX-1 and COX-2 inhibition of Celecoxib in various concentrations.	122
4.19	COX-1 and COX-2 inhibition of ACRH in various concentrations.	123
4.20	COX-1 and COX-2 inhibition of QRF in various concentrations.	124
4.21	COX-1 and COX-2 inhibition of fraction AC-2 (fAC-2) in various concentrations.	125



LIST OF ABBREVIATIONS

5-HETE	5-Hydroxyeicosatetraenoic acid
5-HPETE	5-hydroperoxyeicosatetraenoic acid
5-LOX	5-lipoxygenase
ACR	<i>Ardisia crispa</i> roots
ACRH	<i>Ardisia crispa</i> roots hexane extract
ACUC	Animal Care and Use Committee
Ang1	Angiopoietin 1
ANOVA	Analysis of Variance
bFGF	Basic Fibroblast Growth Factor
COX	Cyclooxygenase
COX-1	Cyclooxygenase-1
COX-2	Cyclooxygenase-2
COX-3	Cyclooxygenase-3
COXIB	Cyclooxygenase inhibitor
CFR	Code of Federal Regulation
DAD	Diode array detector
DMSO	Dimethyl sulfoxide
ECM	Extracellular matrix
EDTA	Ethylenediaminetetraacetic acid
FAP	Familial Adenomatous Polyposis
FCA	Freund's Complete Adjuvant
FDA	Food and Drug Administration
FGF	Fibroblast Growth Factor
FLAP	5-Lipoxygenase Activating Protein
HGF	Hepatocyte growth factor
HPLC	High Performance Liquid Chromatography
IFN- α	Interferon- α
IFN- β	Interferon- β
IFN- γ	Interferon- γ
IL-1	Interleukin-1
IL-10	Interleukin-10
IL-12	Interleukin-12
IL-13	Interleukin-13
IL-1 β	Interleukin-1 β
IL-4	Interleukin-4
IL-6	Interleukin-6
IL-8	Interleukin-8
LAK	Lymphocyte-activated Killer
LIF	Leukemia inhibitory factor
LOX	Lipoxygenase
LSD	Least Significant Difference
LT	Leukotriene
LTA ₄	Leukotriene A ₄
LTB ₄	Leukotriene B ₄
LTC ₄	Leukotriene C ₄
LTD ₄	Leukotriene D ₄
MCP-1	Monocyte Chemotactic Protein-1

MMP	Matrix Metalloproteinase
MMP-2	Matrix Metalloproteinase-2
MMP-8	Matrix Metalloproteinase-8
MVD	Mean Vascular Density
NOS	Nitric Oxide Species
NRP-1	Neuropilin-1
NSAID	Non-Steroidal Anti-Inflammatory Drug
oxLDL	Oxidized Low Density Lipoprotein
p.o.	<i>per os</i> (orally)
PAI-1	Plasminogen Activator Inhibitor-1
PBS	Phosphate Buffer Saline
PDGF	Platelet-derived Growth Factor
PECAM	Platelet Endothelial Cell Adhesion Molecule
PGD ₂	Prostaglandin D ₂
PGE ₂	Prostaglandin E ₂
PGF ₂	Prostaglandin F ₂
PGF _{2α}	Prostaglandin F _{2α}
PGG ₂	Prostaglandin G ₂
PGI ₂	Prostaglandin I ₂
pO ₂	partial Oxygen
QRF	Quinone Rich Fraction
R _f	Retention factor
R _t	Retention time
SEM	Standard Error of Mean
SPARC	Secreted Protein Acidic and Rich in Cysteine
TAE	Tris-acetate-EDTA
TGF-h	Transforming Growth Factor-h
TIMP	Tissue Inhibitor of Metalloproteinases
TLC	Thin Layer Chromatography
TMPD	Tetramethylphenylenediamine
TNF-α	Tumor Necrosis Factor- α
TXA ₂	Thromboxane-A ₂
USC	United States Code
VE-cadherin	Vascular Endothelial-cadherin
VEGF	Vascular Endothelial Growth Factor
VEGFR	Vascular Endothelial Growth Factor Receptor
VEGI	Vascular Endothelial Growth Inhibitor
VI	Vascular Index
WHO	World Health Organization

TABLE OF CONTENTS

	Page
ABSTRACT	ii
ABSTRAK	iv
ACKNOWLEDGEMENTS	vii
APPROVAL	ix
DECLARATION	x
LIST OF TABLES	xi
LIST OF FIGURES	xii
LIST OF ABBREVIATIONS	xv
CHAPTER	
1 INTRODUCTION	1
1.1 Background	1
1.2 Objectives	4
1.3 Hypothesis	5
2 LITERATURE REVIEW	6
2.1 Angiogenesis	6
2.1.1 Introduction	6
2.1.2 Angiogenic cascades	7
2.1.3 Angiogenic mediators	11
2.1.4 Therapeutic intervention	18
2.2 Inflammation	20
2.2.1 Inflammation and angiogenesis	20
2.2.2 Mechanism of inflammation	22
2.2.3 Arachidonic acid metabolizing enzymes	22
2.2.4 Inflammatory mediators	30
2.2.5 Therapeutic intervention	34
2.3. Medicinal food	
2.3.1. Introduction	45
2.3.2 Genus <i>Ardisia</i>	46
2.3.3 <i>Ardisia crispera</i>	50
3 METHODOLOGY	60
3.1 Materials, apparatus and equipments	61
3.1.1 Materials	61
3.1.2 Apparatus and equipments	
3.2 Phytochemistry of <i>Ardisia crispera</i> roots	62
3.2.1 Flow chart	64
3.2.2 Collection, extraction and fractionation of <i>Ardisia crispera</i> roots	65
3.2.3 Phytochemical analysis of ACRH	66
3.2.4 Isolation of rich fraction and bioactive compound using column chromatography	68

	3.2.5 Thin layer chromatography (TLC)	69
	3.2.6 High performance liquid chromatography (HPLC)	71
	3.2.7 Gas chromatography-mass spectrometry (GC-MS)	72
3.3	<i>In vivo</i> studies	73
	3.3.1 Subject	73
	3.3.2 Location of experiment	73
	3.3.3 LD ₅₀ determination	73
	3.3.4 Miles vascular permeability test	75
	3.3.5 Mouse sponge implantation method	79
	3.3.6 Murine air pouch granuloma	82
3.4	<i>In vitro</i> studies	85
	3.4.1 Cyclooxygenase inhibitory assay	85
	3.4.2 Soy lipoxygenase inhibitory assay	87
3.5	Statistical analysis	88
4	RESULTS	89
	4.1 Extraction, fractionation and isolation of rich fraction of rich fractions and bioactive compounds in <i>Ardisia crispa</i> roots	89
	4.2 Lethal dose 50 (LD ₅₀) determination	105
	4.3 Miles vascular permeability test	106
	4.4 Murine air pouch granuloma	109
	4.5 Mouse sponge implantation method	113
	4.6 Cyclooxygenase inhibitory assay	118
	4.7 Soy lipoxygenase inhibitory assay	126
5	DISCUSSION	128
6	CONCLUSION	146
	REFERENCES	149
	APPENDICES	183
	BIODATA OF STUDENT	188
	PUBLICATIONS	189